An observational study in Dry Age Related Macular Degeneration, sponsored by Optina Diagnostics Inc.. Completed at 1 site in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-06.
Sponsored by Optina Diagnostics Inc. · Observational
Among 94 studies in Macular Degeneration with a site in Canada — 11 open to participants now, 16 under way, 7 of them phase 3. Macular Degeneration · Canada.
Among the 94 studies in Macular Degeneration with a site in Canada, this one is the 10th largest by enrollment of the 17 observational ones that give a count, is one of 3 that started in 2022, is one of 17 observational ones, and was the 88th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 238 are open to participants now.
Browse Macular Degeneration studies →11 of the 94 studies in Macular Degeneration with a site in Canada are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Canada, United States, Argentina and 16 more countries
Ages 50+
ADARx Pharmaceuticals, Inc. · Sites in Canada, United States, Australia and 9 more countries
Ages 60+
AbbVie · Sites in Canada, United States, Austria and 14 more countries
Ages 50+
ONL Therapeutics · Sites in Canada, United States, Austria and 9 more countries
Ages 55+
Kriya Therapeutics, Inc. · Sites in Canada, United States, Israel and 1 more country
Ages 55–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 20 · Phase 3 31 · Phase 4 11
First in 1999; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is close to the median of 110 across 409 observational studies indexed under Macular Degeneration.
Median enrollment 180 across the 77 interventional studies, 169 across the 17 observational. Of the 63 that completed or were terminated, 26 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 94 have an industry lead sponsor. The 10 most frequent:
Optina Diagnostics Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Optina Diagnostics Inc. has 1 study filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
5 of the studies in Macular Degeneration with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07129239Phase 3Clinique de Retine de l'estHigh Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM) | 2027-02 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT04762368University of WaterlooLearning Study: Improving Vision in Adults With Macular Degeneration | 2026-12 |
| NCT07917715Clarity Eye InstituteMacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration | 2027-08-16 |
Add all 5 to your calendar (.ics) → With an account.
Among the 94 studies in Macular Degeneration with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational, cross-sectional study is designed to explore the feasibility to extract spatial-spectral features from hyperspectral retinal images captured with Optina Diagnostics' MHRC that are characteristic to the different types of drusenoid deposits associated with dry age-related macular degeneration.
In this observational, cross-sectional, prospective study, participants with dry AMD in at least one eye will undergo a hyperspectral retinal imaging session with the Optina Diagnostics' MHRC in addition to retinal imaging with OCT, used as the gold standard method to identify and classify the drusenoid deposits.
Eligible participants visiting the eye clinic for AMD with dry AMD in at least one eye will be invited to participate in the study. Subjects who sign an informed consent to participate in the study will have their eyes evaluated to confirm that at least one eye is meeting all of the inclusion criteria, and none of the exclusion criteria. The dry AMD status and stage as well as information about eye diseases and conditions will be documented for both eyes. If eligible (no ocular exclusion criteria present in at least one eye), subjects will undergo OCT imaging of the macular region. If the OCT imaging session is successful (as described in the OCT imaging procedure below), the participants will then undergo hyperspectral retinal imaging with the Optina Diagnostics MHRC.
Subjects 50 years old and above with dry AMD with the presence of drusenoid deposits in at least one eye.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for participation, volunteers must conform to all of the following inclusion criteria:
Dry AMD in at least one eye, with at least one type of the following retinal drusenoid deposits: reticular pseudodrusen, soft drusen, hard drusen.
○ The presence of multiple small drusen (\< 63µm) or intermediate drusen (≥63µm and ≥125µm) is sufficient to qualify for this study (Coleman, 2008).
Exclusion Criteria:
Individuals that meet any of the following exclusionary criteria cannot be enrolled:
Any ophthalmologic condition that would prevent obtaining retinal imaging and/or could interfere with the analysis of the MHRC images and OCT images, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with dry AMD in at least one eye will undergo a hyperspectral retinal imaging session with Optina Diagnostics' MHRC in addition to retinal imaging with OCT, used as the gold standard method to identify and classify the drusenoid deposits.
Device: Mydriatic Hyperspectral retinal Camera, (MHRC) and Optical coherence tomography (OCT)
Imaging with the MHRC and optical coherence tomography (OCT).
Creation of a bank of hyperspectral retinal images
Creation of a bank of hyperspectral retinal images that are normalized, registered, segmented and annotated by visual inspection for drusenoid deposit types (soft, hard or reticular pseudodrusen) identified in OCT images re-examined in these re
Time frame: 12 months
Evaluation of the segmented drusenoid deposit
Evaluation of the segmented drusenoid deposit to identify characteristic spatial-spectral features extracted with the use of a method such as, but not limited, to spatial-spectral texture analysis, local spectral normalization, spectral angle mapper (SAM) or Dimension Reduction by Orthogonal Projection for Discrimination (DROP-D) for each type and a creation of classifier.
Time frame: 12 months
Explore if spatial-spectral features identified for different drusenoid deposit
Explore if spatial-spectral features identified for different drusenoid deposit types, and in particular for soft drusen, may be present in locations outside the segmented regions visible to the observer on the hyperspectral images and OCT images. Indeed, these regions could be related to basal linear and basal laminar deposits regions and the OCT scans could be re-examined in these regions to evaluate if there is a visible "split" between the RPE and Bruch's membrane previously associated with basal laminar deposits (Sura et al., 2020).
Time frame: 12 months
Effect of the location each type of drusenoid deposit
Explore the effect of the location each type of drusenoid deposit on the characteristic spatial-spectral features. In this optional sub-study, the drusenoid deposit annotations will include the location based, for example, on circles centered on the fovea within a diameter of 1 mm, 3 mm, 6 mm and beyond 6 mm (if available in the OCT images). (Optional)
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2022 to primary completion in Aug 2023, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Optina Diagnostics Inc.